UK Markets closed

AB Science S.A. (0Q77.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
13.13-0.32 (-2.38%)
At close: 6:29PM BST
Full screen
Previous close13.45
Open13.18
Bid0.00 x 0
Ask0.00 x 0
Day's range13.07 - 13.18
52-week range13.07 - 13.18
Volume7,182
Avg. volumeN/A
Market cap532.352M
Beta (5Y monthly)0.84
PE ratio (TTM)N/A
EPS (TTM)-0.34
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)

    PRESS RELEASE AB SCIENCE GRANTED AUTHORIZATION FROM THE FRENCH HEALTH AUTHORITY (ANSM) TO INITIATE A STUDY OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) SECOND AUTHORIZATION FOR PHASE I/II TRIAL AB18001 PERMITS PATIENT RECRUITMENT FROM STUDY SITES IN FRANCE AND CANADA Paris, 18 October, 2021, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase I/II study (AB18001) evaluating AB8939

  • Globe Newswire

    AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)

    PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO START CLINICAL DEVELOPMENT PROGRAM OF MASITINIB IN MAST CELL ACTIVATION SYNDROME (MCAS) MCAS IS A NEWLY RECOGNIZED DISORDER, DISTINCT FROM BUT CLOSELY RELATED TO SYSTEMIC MASTOCYTOSIS AND FOR WHICH THERE IS A FAR GREATER PREVELANCE IN THE GENERAL POPULATION Paris, October 04, 2021, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that its clinical development program of masitinib in adu

  • Globe Newswire

    AB Science today reports its revenues for the first half of 2021 and provides an update on its activities

    PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION FOR THE FIRST HALF OF 2021 AND THE KEY EVENTS OF THE PERIOD Financial information Operating loss of €6.0 million, a 12.4% reduction in expenses as compared to 2020Significant financial visibility, with a cash position of €17.7 million as of 30 June 2021, plus €3.3 million of 2020 tax credit to be reimbursed by the Public Finance Department and with off-balance sheet commitments received amounting to €90 million Clinical development Prog